
News|Articles|August 7, 2026
Supplements And Featured Publications
- Long-Term Repigmentation Outcomes With OPZELURA® (Ruxolitinib) Cream 1.5% in Nonsegmental Vitiligo Regardless of Baseline Disease Activity
Long-Term Repigmentation Outcomes With OPZELURA® (Ruxolitinib) Cream 1.5% in Nonsegmental Vitiligo Regardless of Baseline Disease Activity
Sponsored by Incyte.
Latest CME
Trending on Managed Healthcare Executive
1
500,000 Medicaid beneficiaries with diabetes to lose coverage by 2034
2
Ashley Holzworth-Nash, Pharm.D., Evernorth
3
Medicaid work requirements and how states may apply them: An in-depth discussion with Eric Levine, M.P.H., of Avalere Health
4
Study shows atopic dermatitis increases shingles risk
5





















